MA71321A - Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie - Google Patents

Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie

Info

Publication number
MA71321A
MA71321A MA71321A MA71321A MA71321A MA 71321 A MA71321 A MA 71321A MA 71321 A MA71321 A MA 71321A MA 71321 A MA71321 A MA 71321A MA 71321 A MA71321 A MA 71321A
Authority
MA
Morocco
Prior art keywords
pcrv
bronchiectasis
treatment
bispecific anti
psl antibodies
Prior art date
Application number
MA71321A
Other languages
English (en)
Inventor
Bret SELLMAN
Antonio Digiandomenico
Wayne Brailsford
Kristoffer OSTRIDGE
Rodney Jason HUGHES
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA71321A publication Critical patent/MA71321A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71321A 2022-06-29 2023-06-28 Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie MA71321A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263367309P 2022-06-29 2022-06-29
PCT/EP2023/067575 WO2024003103A1 (fr) 2022-06-29 2023-06-28 Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie
EP23738427.6A EP4547712A1 (fr) 2022-06-29 2023-06-28 Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie

Publications (1)

Publication Number Publication Date
MA71321A true MA71321A (fr) 2025-04-30

Family

ID=87155664

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71321A MA71321A (fr) 2022-06-29 2023-06-28 Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie

Country Status (11)

Country Link
US (1) US20250382356A1 (fr)
EP (1) EP4547712A1 (fr)
JP (1) JP2025521777A (fr)
KR (1) KR20250044668A (fr)
CN (1) CN119546631A (fr)
AU (1) AU2023300231A1 (fr)
CA (1) CA3260770A1 (fr)
IL (1) IL318036A (fr)
MA (1) MA71321A (fr)
TW (1) TW202417478A (fr)
WO (1) WO2024003103A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025231041A1 (fr) * 2024-04-30 2025-11-06 Renovion, Inc. Méthodes de réduction de symptômes chez des sujets souffrant de bronchiectasie et d'autres maladies pulmonaires

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
WO2013070615A1 (fr) 2011-11-07 2013-05-16 Medlmmune, Llc. Polythérapies utilisant des molécules de liaison anti-psl et pcrv de pseudomonas
US20150284450A1 (en) 2012-11-06 2015-10-08 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
US20170183397A1 (en) 2014-05-05 2017-06-29 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
HK1257193A1 (zh) * 2015-11-30 2019-10-18 Medimmune Limited 用於预防或治疗医源性肺炎的方法

Also Published As

Publication number Publication date
CA3260770A1 (fr) 2024-01-04
AU2023300231A1 (en) 2025-02-13
KR20250044668A (ko) 2025-04-01
IL318036A (en) 2025-02-01
US20250382356A1 (en) 2025-12-18
WO2024003103A1 (fr) 2024-01-04
EP4547712A1 (fr) 2025-05-07
CN119546631A (zh) 2025-02-28
JP2025521777A (ja) 2025-07-10
TW202417478A (zh) 2024-05-01

Similar Documents

Publication Publication Date Title
EP3920889A4 (fr) Exosomes contenant de la télomérase pour le traitement de maladies associées au vieillissement et à un dysfonctionnement d'organe lié à l'âge
MA71708A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
EP3414573A4 (fr) Nouveaux anticorps monoclonaux anti-lam et anti-pim6/lam pour le diagnostic et le traitement d'infections par le bacille de koch
EP4297871A4 (fr) Procédés et compositions pour le traitement de l'agitation
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3573658A4 (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
EP4054589A4 (fr) Procédés de traitement de l'éosophagite à éosinophiles et de réduction de la candidose
EP4138906A4 (fr) Méthodes pour la prophylaxie et le traitement de la covid et de la covid-19
MA48751A (fr) Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
MA54525A (fr) Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
EP4139364A4 (fr) Anticorps bispécifiques pour le traitement de maladies associées à cd47
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
EP4423116A4 (fr) Procédés et compositions pour le traitement du glioblastome
EP3880709A4 (fr) Schéma posologique d'un anticorps anti-lag3 et polythérapie avec un anticorps anti-pd-1 pour le traitement du cancer
EP3727374A4 (fr) Association d'un anticorps anti-pd-l1 et d'un inhibiteur de l'ido1 pour le traitement du cancer
EP4351610A4 (fr) Procédé et composition pour la prévention et le traitement de la covid-19 et de la covid longue
EP4099997A4 (fr) Méthodes et compositions pour le traitement de maladies
EP3500282A4 (fr) Composition anti-inflammatoire pour le traitement d'une inflammation articulaire aiguë et son procédé de préparation
EP4097137A4 (fr) Combinaisons d'inhibiteurs d'egfr et d'inhibiteurs de ror1 pour le traitement du cancer
EP4340881A4 (fr) Anticorps pour le traitement d'alpha-synucléinopathies
EP4210750A4 (fr) Méthodes et agents thérapeutiques pour le traitement d'un infarctus du myocarde
CA3249951A1 (fr) Compositions pharmaceutiques pour le traitement de la douleur
MA71376A (fr) Produit de fermentation pour le traitement de maladies inflammatoires